Curriculum Vitae
Name: Ling-Ming Tseng, MD
Attending Surgeon,
Division of General Surgery,
Department of Surgery, Veterans General Hospital-Taipei,
Associateprofessor, National Yang-Ming University,
Associateprofessor, National Defense Medical Center
Taiwan, Republic of China
Education: 1982 .08 – 1989.07 National Defense Medical Center M.D.
Address of affiliated institution: No.201, Sec. 2, Shih-Pai Rd.(Shi-Pai Rd.). Taipei (11217), Taiwan, R.O.C.
Surgical & Research Training:
1992-1996 Surgical Resident in Veterans General Hospital, Taipei
1996-1997 Chief Resident in Surgery in Veterans General Hospital, Taipei, ROC
1998- Attending Surgeon
Division of General Surgery, Department of Surgery,
Veterans General Hospital-Taipei, Taiwan, ROC
2005.12 -2006.11
Visiting Scientist of Department of Surgical Oncology & Department of Molecular& Cellular Oncology, MD Anderson Cancer Center, the University of Texas, USA
Current Appointments:
1998- Attending Surgeon in Division of General Surgery, Department of Surgery, Veterans General Hospital-Taipei
1998- Committeeman of Breast Cancer Committee, Taiwan Cooperative Oncology Group, Division of Cancer Research, National Health Research Institutes
2000-2009 Secretary General of Taiwan association of endocrine surgeons
2007-2010 Council of The Breast Cancer Society of Taiwan
2009- Council of Taiwan association of endocrine surgeons
2010- Secretary General of The Breast Cancer Society of Taiwan
Certification:
1996 Chinese Board of Surgery
1997 Chinese Board of Surgical Gastroenterology
1999 Chinese Board of Surgical Breast
2000 Chinese Board of Surgical endocrinology
2005-2006 Visiting Scientist of Molecular & cellular Oncology, Surgical Oncology, MD Anderson Cancer Center
2012 The Board of Surgical Oncology of the Chinese Oncology Society andTaiwan Surgical Association
Membership in Medical and Scientific Society:
1. Taiwan Surgical Association
2. Taiwan Association of Gastrointestinal Surgery
3. Taiwan Association of Endocrine Surgeons
4. The Breast Cancer Society of Taiwan
5. The Chinese Oncology Society
Textbook
1. Endocrine Surgery Principles and Practice Hubbard, Johnathan; Inabnet, William B.; Lo, Chung-Yau (Eds.) Springer Specialist Surgery Series
2. Pain Management Yearbook 2013 Joav Merrick, MD, MMedSci, DMSc (Eds.) Pediatrics, Child and Adolescent Health (Pub. Date:2014 - 3rd Quarter)
Awards
1. / 2014 Excellent paper presentation of breast of Surgery2. / 2013 Excellent paper presentation of breast of Surgery
3. / 2013 Outstanding Paper Award of Merck
4. / 2013 Excellent MD Physician Award of Taipei Veterans General Hospital
5. / 2012 Second Medical Innovation Award of Taipei Veterans General Hospital
6. / 2012 Excellent paper presentation of breast of Surgery
7. / 2012 Outstanding Paper Award of Merck
Publications (*correspondence):
1. /Wu YT,Chen ST,Chen CJ,Kuo YL,Tseng LM,Chen DR,Kuo SJ,Lai HW. Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy. World J Surg Oncol.2014 Nov 10;12(1):335(I F=1.20)
2. / Chou HP,Tseng LM Outcome of mammography screening in Taiwan J Chin Med Assoc.2014 Oct;77(10):503-43. /
Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW, Tseng LM*, Chen KF. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A dependent phospho-Akt inactivation in estrogen-receptor negative human breast cancer cells. Breast Cancer Res. 2014 Sep 17;16(5):431. (I F=5.881；R/C=25/202，Oncology)
4. /Liang SY, Wu SF, Chao TC,Tseng LM, Wu WW, Wang TJ, Lu YY. The Impact of Pain on the Quality of Life of Taiwanese Oncology Patients. Pain Manag Nurs. 2014 Sep 3. pii: S1524-9042(14)00093-9. (I F=1.787)
5. /Yeh DC, Chen DR, Chao TY, Chen SC, Wang HC, Rau KM, Feng YH, Chang YC, Lee KD, Ou-Yang F, Kuo WH, Chang KJ, Lin YC,Tseng LM*, Hou MF. EORTC QLQ-BM22 Quality of Life Evaluation and Pain Outcome in Patients with Bone Metastases from Breast Cancer Treated with Zoledronic Acid. In Vivo. 2014 09-10;28(5):1001-1004 (I F=1.148)
6. / Noomhorm N, Chang CJ, Wen CS, Wang JY, Chen JL,Tseng LM, Chen WS, Chiu JH, Shyr YM In vitro and in vivo effects of xanthorrhizol on human breast cancer mcf-7 cells treated with tamoxifen. J Pharmacol Sci. 2014;125(4):375-85 (I F=3.007；R/C=76/254，Pharmacology & Pharmacy)7. / Chiu JH, Chang CJ, Wu JC, Liu HJ, Wen CS, Hsu CH, Chen JL,Tseng LM*, Chen WS, Shyr YM. Screening to identify Commonly Used Chinese Herbs that affect ERBB2 and ESR1 Gene Expression using the Human Breast Cancer MCF-7 Cell Line. Evidence-Based Complementary and Alternative Medicine Epub 2014 May 27 (I F=1.722；R/C=8/22，INTEGRATIVE & COMPLEMENTARY MEDICINE)
8. /
Liu CY, Su JC, Ni MH,Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Hung MH, Shiau CW, Chen KF. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. Breast Cancer Res Treat.2014 Jul;146(1):71-84. (I F=5.872；R/C=26/197，ONCOLOGY)
9. / Fu CH, Lin RJ, Yu J, Chang WW, Liao GS, Chang WY,Tseng LM, Tsai YF, Yu JC, Yu AL A novel oncogenic role of inositol phosphatase SHIP2 in ER-Negative breast cancer stem cells: Involvement of JNK/Vimentin activation. Stem Cells. 2014 May 6. doi: 10.1002/stem.173510. / Hung MH, Liu CY, Shiau CY, Hsu CY, Tsai YF, Wang YL, Tai LC, King KL, Chao TC, Chiu JH, Su CH, Lo SS, Tzeng CH, Shyr YM, Tseng LM* Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients. PLoS ONE 9(2): e89389 (I F=3.730；R/C=7/56，MULTIDISCIPLINARY SCIENCES)
11. /
Chen JL, Chang CJ, Wang JY, Wen CS, Tseng LM, Chang WC, Noomhorm N, Liu HJ, Chen WS, Chiu JH, Shyr YM In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen. Integr Cancer Ther. 2014 Feb 12;13(3):226-239. (I F=2.354；R/C=4/22 in Integrative & Complementary Medicine | 108/196 in Oncology)
12. / Cramarossa G, Zeng L, Zhang L, Tseng LM, Hou MF, Fairchild A, Vassiliou V, Jesus-Garcia R, El-Din MA, Kumar A, Forges F, Chie WC, Sahgal A, Lam H, Pulenzas N, Chow E Predictive factors of overall quality of life in advanced cancer patients using EORTC QLQ-C30. Expert Rev Pharmacoecon Outcomes Res. 2013 Dec 10.13. / Chao TC, Chen DR, Chao TY, Chen SC, Yeh DC, Wang HC, Huang WT, Rau KM, Chang KJ, Yang TL, Lee KD, Tai CJ, Tseng LM, Hou MF Quality of Life Assessment in Taiwanese Patients with Bone Metastases from Breast Cancer Receiving Zoledronic Acid. Anticancer Res. 2013 Dec;33(12):5543-5547. (I F=1.872)
14. / Lan YC, Chang CL, Sung MT, Yin PH, Hsu CC, Wang KC, Lee HC, Tseng LM*, Chi CW. Zoledronic Acid-induced Cytotoxicity Through Endoplasmic Reticulum Stress Triggered REDD1-mTOR Pathway in Breast Cancer Cells. Anticancer Res. 2013 Sep;33(9):3807-14. (I F=1.872)
15. / Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Research 2013 Aug 12;15(4):R63 (I F=5.872；R/C=26/197，ONCOLOGY)
16. / Tsai CH, Yang CW, Wang JY, Tsai YF, Tseng LM*, King KL, Chen WS, Chiu JH, Shyr YM Timosaponin AIII Suppresses Hepatocyte Growth Factor-Induced Invasive Activity through Sustained ERK Activation in Breast Cancer MDA-MB-231 Cells. Evid Based Complement Alternat Med. Epub 2013 Jun 25.
17. / Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L. Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of βIII-Tubulin Expression as a Predictive Marker. Oncologist. 2013;18(7):787-94
18. / Wong E, Chow E, Zhang L, Bedard G, Lam K, Fairchild A, Vassiliou V, Alm El-Din MA, Jesus-Garcia R, Kumar A, Forges F, Tseng LM, Hou MF, Chie WC, Bottomley A. Factors influencing health related quality of life in cancer patients with bone metastases J Palliat Med. 2013 Aug;16(8):915-21
19. / Lai HW, Tseng LM, Chang TW, Kuo YL, Hsieh CM, Chen ST, Kuo SJ, Su CC, Chen DR The prognostic significance of metaplastic carcinoma of the breast (MCB) - A case controlled comparison study with infiltrating ductal carcinoma. Breast.2013 Jun 17
20. / Lam K, Chow E, Zhang L, Wong E, Bedard G, Fairchild A, Vassiliou V, El-Din MA, Jesus-Garcia R, Kumar A, Forges F, Tseng LM, Hou MF, Chie WC, Bottomley A. Determinants of quality of life in advanced cancer patients with bone metastases undergoing palliative radiation treatment. Support Care Cancer.2013 Jun 19
21. / Huang SM, Chien LY, Tai CJ, Tseng LM, Chen PH, Tai CJ. Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies. Evid Based Complement Alternat Med. pub 2013 Mar 21
22. / Lai HW,Wu HK,Kuo SJ,Chen ST,Tseng HS,Tseng LM,Chen DR. Differences in accuracy and underestimation rates for 14- versus 16-gauge core needle biopsies in ultrasound-detectable breast lesions. Asian J Surg.2013 Apr;36(2):83-8
23. / Lam K,Zeng L,Zhang L,Tseng LM,Hou MF,Fairchild A,Vassiliou V,Jesus-Garcia R,El-Din MA,Kumar A,Pharmd FF,Chie WC,Sahgal A,Poon M,Chow E. Predictive Factors of Overall Well-Being Using the EORTC QLQ-C15-PAL Extracted from the EORTC QLQ-C30. J Palliat Med.2013 Mar 4.
24. / Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, Li H, Lin YC, Chang HK, Chao TC,
Ouyang F, Hou MF Distant metastasis in triple-negative breast cancer. Neoplasma. 2013;60(3):290-4
25. / Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R, Liu D Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-stage Breast Cancer. Clin Cancer Res. 2013 Jan 22.
26. / Chen JL, Wang JY, Tsai YF, Lin YH, Tseng LM*, Chang WC, King KL, Chen WS, Chiu JH, Shyr YM In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab. Menopause. 2013 Jan 21 (IF=3.163；R/C=10/78，OBSTETRICS & GYNECOLOGY)
27. / Hsu HY,Lin TY,Hwang PA,Tseng LM,Chen RH,Tsao SM,Hsu J. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer. Carcinogenesis.2013 Jan 18
28. / Ke CC, Liu RS, Yang AH, Liu CS, Chi CW, Tseng LM, Tsai YF, Ho JH, Lee CH, Lee OK. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):61-71
29. / Lai YC, Hsu CY, Chou YH, Tiu CM, Tseng LM, Wang HK, Chiou HJ. Sonographic presentations of metaplastic breast cancers. J Chin Med Assoc. 2012 Nov;75(11):589-94.
30. / Huang SM, Tai CJ, Lin KC, Tai CJ, Tseng LM, Chien LY. A Comparative Study of Symptoms and Quality of Life Among Patients With Breast Cancer Receiving Target, Chemotherapy, or Combined Therapy. Cancer Nurs. 2012 Oct 5
31. / Zeng L, Chow E, Bedard G, Zhang L, Fairchild A, Vassiliou V, Alm El-Din MA, Jesus-Garcia R, Kumar A, Forges F,Tseng LM, Hou MF, Chie WC, Bottomley A. Quality of Life After Palliative Radiation Therapy for Patients With Painful Bone Metastases: Results of an International Study Validating the EORTC QLQ-BM22. Int J Radiat Oncol Biol Phys.2012 Jul 3 (IF 4.105)
32. / Zeng L, Chow E, Zhang L, Tseng LM, Hou MF, Fairchild A, Vassiliou V, Jesus-Garcia R, El-Din MA, Kumar A, Forges F, Chie WC, Bedard G, Bottomley A. An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases. Support Care Cancer. 2012 May 6
33. / Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 2012 Apr 26;14(2):R68.
(I F=5.87；R/C= 26/196，ONCOLOGY)
34. / Lo WL, Chu PY, Lee TH, Su TL, Chien Y, Chen YW, Huang PI, Tseng LM, Tu PH, Kao SY, Lo JF A Combined DNA-Affinic Molecule and N-Mustard Alkylating Agent Has an Anti-Cancer Effect and Induces Autophagy in Oral Cancer Cells. Int J Mol Sci. 2012;13(3):3277-90.
35. / Lo WL, Chien Y, Chiou GY,Tseng LM, Hsu HS, Chang YL, Lu KH, Chien CS, Wang ML, Chen YW, Huang PI, Hu FW, Yu CC, Chu PY, Chiou SH Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous Cell carcinoma-derived cancer stem cells. Biomaterials. 2012 May;33(14):3693-709.
36. / Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, Chi CW, Chiou SH, Yang DM, Lee CH. Targeting STAT3 Pathway by Cucurbitacin I Diminishes Self-renewaling and Radiochemoresistant Abilities in Thyroid Cancer-derived CD133+ Cells. J Pharmacol Exp Ther. 2012 May;341(2):410-23.
37. / Chiou GY, Cherng JY, Hsu HS, Wang ML, Tsai CM, Lu KH, Chien Y, Hung SC, Chen YW, Wong CI, Tseng LM, Huang PI, Yu CC, Hsu WH, Chiou SH Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release. 2012 Apr 30;159(2):240-50.
38. / Chuang HH, Yang CH, Tsay YG, Hsu CY, Tseng LM, Chang ZF, Lee HH. ROCKII serine 1366 phosphorylation reflects the activation status. Biochem J. 2012 Apr 1;443(1):145-51.
39 / Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; on behalf of the NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Lancet. 2012 Jan 16.
( I F=39.060；R/C= 2/151，MEDICINE, GENERAL & INTERNAL)
40 / Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011 Dec 6.
41 / Chang CJ, Chien Y, Lu KH, Chang SC, Chou YC, Huang CS, Chang CH, Chen KH, Chang YL, Tseng LM, Song WS, Wang JJ, Lin JK, Huang PI, Lan YT. Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. Biochem Biophys Res Commun. 2011 Oct 19
42 / Wu CL, Tiu CM, Chen JD, Tseng LM, Chou YH, Chang CY. Gauzoma of the Breast. Breast J. 2011 Sep 23